OBJECTIVE: This analysis focuses on efficacy and safety data obtained from studies of
duloxetine for the treatment of major depressive disorder (MDD) within the approved dose …

Existing therapies for major depressive disorder (MDD) have either limited efficacy and/or
poor tolerability. The present study examined the effects of duloxetine, a potent and …

Background Major depressive disorder (MDD) is a chronic and highly disabling condition.
Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients …

Objectives: This post hoc analysis compared how patients and physicians estimate disease
severity and global improvement during 8 weeks of treatment for major depressive disorder …

Painful physical symptoms are common features of major depressive disorder and may be
the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) …

Objective: Debate continues regarding whether onset of analgesia is faster than
antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from …

Abstract In treating Major Depressive Disorder with associated painful physical symptoms
(PPS), the effect of duloxetine on PPS has been shown to decompose into a direct effect on …

Background: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT)
and norepinephrine (NE) that has previously been shown to be effective in the acute …

Objective: In placebo-controlled clinical trials, duloxetine has been shown to be effective and
well-tolerated in patients with major depressive disorder (MDD). However, patients in …

Aims: This was a post hoc analysis to determine whether baseline severity of depression
influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to …